Bortezomib for Injection

DRUG3 trials

Sponsors

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Massachusetts General Hospital, Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Multiple MyelomaNewly Diagnosed Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed or Refractory Multiple MyelomaTransplant Ineligible

Phase 1

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Relapsed or Refractory Multiple Myeloma

Start: 2021-10-20End: 2024-06-20Target: 60Updated: 2022-02-01

Phase 2

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Not yet recruitingNCT07247097

Massachusetts General HospitalMultiple Myeloma, Newly Diagnosed Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM) +1

Start: 2026-08-01End: 2035-12-01Target: 160Updated: 2026-06-23

Phase 3

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Not yet recruitingNCT07623798

Innovent Biologics (Suzhou) Co. Ltd.Relapsed or Refractory Multiple Myeloma

Start: 2026-06-05End: 2029-12-31Target: 255Updated: 2026-06-03

Related Papers

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial

Cancer Medicine2025-04-01